Literature DB >> 29696732

Seshat: A Web service for accurate annotation, validation, and analysis of TP53 variants generated by conventional and next-generation sequencing.

Tuomas Tikkanen1, Bernard Leroy2, Jean Louis Fournier2, Rosa Ana Risques3, Jitka Malcikova4,5, Thierry Soussi2,6,7.   

Abstract

Accurate annotation of genomic variants in human diseases is essential to allow personalized medicine. Assessment of somatic and germline TP53 alterations has now reached the clinic and is required in several circumstances such as the identification of the most effective cancer therapy for patients with chronic lymphocytic leukemia (CLL). Here, we present Seshat, a Web service for annotating TP53 information derived from sequencing data. A flexible framework allows the use of standard file formats such as Mutation Annotation Format (MAF) or Variant Call Format (VCF), as well as common TXT files. Seshat performs accurate variant annotations using the Human Genome Variation Society (HGVS) nomenclature and the stable TP53 genomic reference provided by the Locus Reference Genomic (LRG). In addition, using the 2017 release of the UMD_TP53 database, Seshat provides multiple statistical information for each TP53 variant including database frequency, functional activity, or pathogenicity. The information is delivered in standardized output tables that minimize errors and facilitate comparison of mutational data across studies. Seshat is a beneficial tool to interpret the ever-growing TP53 sequencing data generated by multiple sequencing platforms and it is freely available via the TP53 Website, http://p53.fr or directly at http://vps338341.ovh.net/.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  HGVS variant nomenclature; TP53 variants; database; variant annotation

Mesh:

Substances:

Year:  2018        PMID: 29696732     DOI: 10.1002/humu.23543

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  11 in total

1.  Fam83F induces p53 stabilisation and promotes its activity.

Authors:  Mohammed Salama; Diego Benitez-Riquelme; Seham Elabd; Leonel Munoz; Ping Zhang; Matthias Glanemann; Maria Caterina Mione; Robert Goldin; Thierry Soussi; Gary Davidson; Christine Blattner
Journal:  Cell Death Differ       Date:  2019-01-28       Impact factor: 15.828

2.  Ultra-Sensitive TP53 Sequencing for Cancer Detection Reveals Progressive Clonal Selection in Normal Tissue over a Century of Human Lifespan.

Authors:  Jesse J Salk; Kaitlyn Loubet-Senear; Elisabeth Maritschnegg; Charles C Valentine; Lindsey N Williams; Jacob E Higgins; Reinhard Horvat; Adriaan Vanderstichele; Daniela Nachmanson; Kathryn T Baker; Mary J Emond; Emily Loter; Maria Tretiakova; Thierry Soussi; Lawrence A Loeb; Robert Zeillinger; Paul Speiser; Rosa Ana Risques
Journal:  Cell Rep       Date:  2019-07-02       Impact factor: 9.423

3.  Colorectal Cancer Is Associated with the Presence of Cancer Driver Mutations in Normal Colon.

Authors:  Julia Matas; Brendan Kohrn; Jeanne Fredrickson; Kelly Carter; Ming Yu; Ting Wang; Xianyong Gui; Thierry Soussi; Victor Moreno; William M Grady; Miguel A Peinado; Rosa Ana Risques
Journal:  Cancer Res       Date:  2022-04-15       Impact factor: 13.312

4.  Characterization of TP53 mutations in Pap test DNA of women with and without serous ovarian carcinoma.

Authors:  Jeffrey D Krimmel-Morrison; Talayeh S Ghezelayagh; Shenyi Lian; Yuezheng Zhang; Jeanne Fredrickson; Daniela Nachmanson; Kathryn T Baker; Marc R Radke; Enna Hun; Barbara M Norquist; Mary J Emond; Elizabeth M Swisher; Rosa Ana Risques
Journal:  Gynecol Oncol       Date:  2019-12-12       Impact factor: 5.482

5.  Characterizing TP53 mutations in ovarian carcinomas with and without concurrent BRCA1 or BRCA2 mutations.

Authors:  Talayeh S Ghezelayagh; Kathryn P Pennington; Barbara M Norquist; Nithisha Khasnavis; Marc R Radke; Mark R Kilgore; Rochelle L Garcia; Ming Lee; Ronit Katz; Kimberly K Leslie; Rosa Ana Risques; Elizabeth M Swisher
Journal:  Gynecol Oncol       Date:  2020-12-26       Impact factor: 5.482

Review 6.  TP53 aberrations in chronic lymphocytic leukemia: an overview of the clinical implications of improved diagnostics.

Authors:  Elias Campo; Florence Cymbalista; Paolo Ghia; Ulrich Jäger; Sarka Pospisilova; Richard Rosenquist; Anna Schuh; Stephan Stilgenbauer
Journal:  Haematologica       Date:  2018-11-15       Impact factor: 9.941

7.  Clinical Utility of a Cell-Free DNA Assay in Patients With Colorectal Cancer.

Authors:  Ren-Hao Chan; Peng-Chan Lin; Shang-Hung Chen; Shao-Chieh Lin; Po-Chuan Chen; Bo-Wen Lin; Meng-Ru Shen; Yu-Min Yeh
Journal:  Front Oncol       Date:  2021-03-19       Impact factor: 6.244

8.  Low-burden TP53 mutations in CLL: clinical impact and clonal evolution within the context of different treatment options.

Authors:  Jitka Malcikova; Sarka Pavlova; Barbara Kunt Vonkova; Lenka Radova; Karla Plevova; Jana Kotaskova; Karol Pal; Barbara Dvorackova; Marcela Zenatova; Jakub Hynst; Eva Ondrouskova; Anna Panovska; Yvona Brychtova; Kristyna Zavacka; Boris Tichy; Nikola Tom; Jiri Mayer; Michael Doubek; Sarka Pospisilova
Journal:  Blood       Date:  2021-12-23       Impact factor: 25.476

Review 9.  Landscape of TP53 Alterations in Chronic Lymphocytic Leukemia via Data Mining Mutation Databases.

Authors:  Thierry Soussi; Panagiotis Baliakas
Journal:  Front Oncol       Date:  2022-02-16       Impact factor: 6.244

10.  A pedigree-based prediction model identifies carriers of deleterious de novo mutations in families with Li-Fraumeni syndrome.

Authors:  Fan Gao; Xuedong Pan; Elissa B Dodd-Eaton; Carlos Vera Recio; Matthew D Montierth; Jasmina Bojadzieva; Phuong L Mai; Kristin Zelley; Valen E Johnson; Danielle Braun; Kim E Nichols; Judy E Garber; Sharon A Savage; Louise C Strong; Wenyi Wang
Journal:  Genome Res       Date:  2020-08-18       Impact factor: 9.043

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.